|
1
|
Schadendorf D, van Akkooi ACJ, Berking C,
Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A and Ugurel
S: Melanoma. Lancet. 392:971–984. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spagnolo F, Ghiorzo P and Queirolo P:
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic
melanoma. Oncotarget. 5:10206–10221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ascierto PA, Kirkwood JM, Grob JJ, Simeone
E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM and
Mozzillo N: The role of BRAF V600 mutation in melanoma. J Transl
Med. 10:852012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pratilas CA, Taylor BS, Ye Q, Viale A,
Sander C, Solit DB and Rosen N: (V600E)BRAF is associated with
disabled feedback inhibition of RAF-MEK signaling and elevated
transcriptional output of the pathway. Proc Natl Acad Sci USA.
106:4519–4524. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagle N, Emery C, Berger MF, Davis MJ,
Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE,
Hahn WC, et al: Dissecting therapeutic resistance to RAF inhibition
in melanoma by tumor genomic profiling. J Clin Oncol. 29:3085–3096.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Griffin M, Scotto D, Josephs DH, Mele S,
Crescioli S, Bax HJ, Pellizzari G, Wynne MD, Nakamura M, Hoffmann
RM, et al: BRAF inhibitors: Resistance and the promise of
combination treatments for melanoma. Oncotarget. 8:78174–78192.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson DB, Flaherty KT, Weber JS, Infante
JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH,
et al: Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib)
in patients with BRAFV600-mutant melanoma experiencing progression
with single-agent BRAF inhibitor. J Clin Oncol. 32:3697–3704. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Robert C, Grob JJ, Stroyakovskiy D,
Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V,
Schachter J, Garbe C, Bondarenko I, et al: Five-year outcomes with
dabrafenib plus trametinib in metastatic melanoma. N Engl J Med.
381:626–636. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roesch A, Fukunaga-Kalabis M, Schmidt EC,
Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T
and Herlyn M: A temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor growth. Cell.
141:583–594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arozarena I and Wellbrock C: Phenotype
plasticity as enabler of melanoma progression and therapy
resistance. Nat Rev Cancer. 19:377–391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Das Thakur M, Salangsang F, Landman AS,
Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M and Stuart
DD: Modelling vemurafenib resistance in melanoma reveals a strategy
to forestall drug resistance. Nature. 494:251–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Menon DR, Das S, Krepler C, Vultur A,
Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, et al:
A stress-induced early innate response causes multidrug tolerance
in melanoma. Oncogene. 34:45452015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rolih V, Barutello G, Iussich S, De Maria
R, Quaglino E, Buracco P, Cavallo F and Riccardo F: CSPG4: A
prototype oncoantigen for translational immunotherapy studies. J
Transl Med. 15:1512017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ilieva KM, Cheung A, Mele S, Chiaruttini
G, Crescioli S, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE,
et al: Chondroitin sulfate proteoglycan 4 and its potential as an
antibody immunotherapy target across different tumor types. Front
Immunol. 8:19112017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ross AH, Cossu G, Herlyn M, Bell JR,
Steplewski Z and Koprowski H: Isolation and chemical
characterization of a melanoma-associated proteoglycan antigen.
Arch Biochem Biophys. 225:370–383. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campoli MR, Chang CC, Kageshita T, Wang X,
McCarthy JB and Ferrone S: Human high molecular
weight-melanoma-associated antigen (HMW-MAA): A melanoma cell
surface chondroitin sulfate proteoglycan (MSCP) with biological and
clinical significance. Crit Rev Immunol. 24:267–296. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Price MA, Colvin Wanshura LE, Yang J,
Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA and
McCarthy JB: CSPG4, a potential therapeutic target, facilitates
malignant progression of melanoma. Pigment Cell Melanoma Res.
24:1148–1157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stallcup WB and Dahlin-Huppe K:
Chondroitin sulfate and cytoplasmic domain-dependent membrane
targeting of the NG2 proteoglycan promotes retraction fiber
formation and cell polarization. J Cell Sci. 114:2315–2325.
2001.PubMed/NCBI
|
|
22
|
Iida J, Wilhelmson KL, Ng J, Lee P,
Morrison C, Tam E, Overall CM and McCarthy JB: Cell surface
chondroitin sulfate glycosaminoglycan in melanoma: Role in the
activation of pro-MMP-2 (pro-gelatinase A). Biochem J. 403:553–563.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iida J, Meijne AM, Oegema TR Jr, Yednock
TA, Kovach NL, Furcht LT and McCarthy JB: A role of chondroitin
sulfate glycosaminoglycan binding site in alpha4beta1
integrin-mediated melanoma cell adhesion. J Biol Chem.
273:5955–5962. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang J, Price MA, Neudauer CL, Wilson C,
Ferrone S, Xia H, Iida J, Simpson MA and McCarthy JB: Melanoma
chondroitin sulfate proteoglycan enhances FAK and ERK activation by
distinct mechanisms. J Cell Biol. 165:881–891. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Price MA, Li GY, Bar-Eli M, Salgia
R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA and McCarthy
JB: Melanoma proteoglycan modifies gene expression to stimulate
tumor cell motility, growth, and epithelial-to-mesenchymal
transition. Cancer Res. 69:7538–7547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jordaan S, Chetty S, Mungra N, Koopmans I,
van Bommel PE, Helfrich W and Barth S: CSPG4: A target for
selective delivery of human cytolytic fusion proteins and TRAIL.
Biomedicines. 5:372017. View Article : Google Scholar
|
|
27
|
Hoffmann RM, Crescioli S, Mele S, Sachouli
E, Cheung A, Chui CK, Andriollo P, Jackson PJM, Lacy KE, Spicer JF,
et al: A novel antibody-drug conjugate (ADC) delivering a DNA
mono-alkylating payload to chondroitin sulfate proteoglycan
(CSPG4)-expressing melanoma. Cancers (Basel). 12:10292020.
View Article : Google Scholar
|
|
28
|
Wang Y, Geldres C, Ferrone S and Dotti G:
Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen
receptor-based T-cell immunotherapy of solid tumors. Expert Opin
Ther Targets. 19:1339–1350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hafner C, Breiteneder H, Ferrone S,
Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K,
Zielinski CC, et al: Suppression of human melanoma tumor growth in
SCID mice by a human high molecular weight-melanoma associated
antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer.
114:426–432. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pucciarelli D, Lengger N, Takacova M,
Csaderova L, Bartosova M, Breiteneder H, Pastorekova S and Hafner
C: Anti-chondroitin sulfate proteoglycan 4-specific antibodies
modify the effects of vemurafenib on melanoma cells differentially
in normoxia and hypoxia. Int J Oncol. 47:81–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu L, Favoino E, Wang Y, Ma Y, Deng X and
Wang X: The CSPG4-specific monoclonal antibody enhances and
prolongs the effects of the BRAF inhibitor in melanoma cells.
Immunol Res. 50:294–302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ampofo E, Schmitt BM, Menger MD and
Laschke MW: The regulatory mechanisms of NG2/CSPG4 expression. Cell
Mol Biol Lett. 22:42017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Campoli M, Ferrone S and Wang X:
Functional and clinical relevance of chondroitin sulfate
proteoglycan 4. Adv Cancer Res. 109:73–121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J, Price MA, Wanshura LEC, He J, Yi
M, Welch DR, Li G, Conner S, Sachs J, Turley EA and McCarthy JB:
Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and
growth requires a cysteine in the core protein transmembrane
domain. Melanoma Res. 29:365–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Makagiansar IT, Williams S, Mustelin T and
Stallcup WB: Differential phosphorylation of NG2 proteoglycan by
ERK and PKCalpha helps balance cell proliferation and migration. J
Cell Biol. 178:155–165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Luo W, Wang X, Kageshita T, Wakasugi S,
Karpf AR and Ferrone S: Regulation of high molecular
weight-melanoma associated antigen (HMW-MAA) gene expression by
promoter DNA methylation in human melanoma cells. Oncogene.
25:2873–2884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yadavilli S, Scafidi J, Becher OJ,
Saratsis AM, Hiner RL, Kambhampati M, Mariarita S, MacDonald TJ,
Codispoti KE, Magge SN, et al: The emerging role of NG2 in
pediatric diffuse intrinsic pontine glioma. Oncotarget.
6:12141–12155. 2015. View Article : Google Scholar : PubMed/NCBI
|
